Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

43.19 +1.48 (+3.55%)
Official Closing Price Updated: 7:00 PM EDT, Sep 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 12,971,330
Open 41.98
Bid (Size) 43.44 (1,100)
Ask (Size) 43.48 (100)
Prev. Close 41.71
Today's Range 41.96 - 43.44
52wk Range 35.12 - 64.16
Shares Outstanding N/A
Dividend Yield 5.90%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Wall Street Sees a Huge Rebound for Viking Therapeutics. Here's Why Analysts Are So Optimistic. ↗
The weight loss market is highly competitive, but Viking only needs to carve out a small niche in it with VK2735 in order to generate significant value for investors. 
Via The Motley Fool
News headline image
This Trend is Excellent News for Eli Lilly and Its Investors ↗
Eli Lilly and Novo Nordisk are vying for a new part of the weight loss drug market. 
Via The Motley Fool

Performance

YTD
-17.6%
-17.6%
1 Month
-3.8%
-3.8%
3 Month
-0.8%
-0.8%
6 Month
+15.3%
+15.3%
1 Year
-24.5%
-24.5%

More News

Read More
News headline image
Where Will Novo Nordisk Be in 5 Years as the GLP-1 Market Gets More Crowded? ↗
Via The Motley Fool
Topics Economy
News headline image
Eli Lilly's Momentum Looks Unstoppable -- but 1 Factor Could Change Everything ↗
Via The Motley Fool
News headline image
3 Absurdly Cheap Growth Stocks to Buy Before the End of 2026 ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Novo Nordisk vs. Regeneron Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Novo Nordisk May Be Poised to Outpace Eli Lilly With This Key Catalyst ↗
Via The Motley Fool
News headline image
Could This New Opportunity Be Worth Billions for Novo Nordisk? ↗
Via The Motley Fool
News headline image
AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026? ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Institutional Investors Are Loading Up on Madrigal Pharmaceuticals Stock. Should You? ↗
Via The Motley Fool
News headline image
Analysts Have a $92 Target on Viking Therapeutics. Here's What Has to Go Right to Get There. ↗
Via The Motley Fool
News headline image
Is Novo Nordisk Stock Still Too Cheap for Investors to Ignore? ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
3 of the Best Growth Stocks to Buy for Less Than $100 Right Now ↗
Via The Motley Fool
News headline image
Eli Lilly Has Been on an Acquisition Spree. How Much Could Its Latest Deals Boost the Stock? ↗
Via The Motley Fool
News headline image
Viking Therapeutics Trades Well Below Its Wall Street Targets. Here's the Skeptics' Case. ↗
Via The Motley Fool
News headline image
2 Stocks Down 8% or More That Are Screaming Buys Right Now ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Should Eli Lilly Investors Be Worried About a Threat From Amylyx? ↗
Via The Motley Fool
News headline image
Has Novo Nordisk Finally Found the Catalyst That Could Flip the Script on Eli Lilly? ↗
Via The Motley Fool
News headline image
Billionaire Stanley Druckenmiller Is Quietly Loading Up on Healthcare Stocks -- Here's What His New Positions Reveal ↗
Via The Motley Fool
News headline image
Eli Lilly and Novo Nordisk Can't Treat This Form of Obesity. Billionaire Stanley Druckenmiller Is Betting Rhythm Pharmaceuticals Can ↗
Via The Motley Fool
News headline image
2 Biotech Stocks Shaping Up for Major Breakouts ↗
Via MarketBeat
Topics ETFs
News headline image
A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
From Equity Insider
Via GlobeNewswire
News headline image
3 Absurdly Cheap Dividend Stocks to Buy for Under $100 Right Now ↗
Via The Motley Fool
News headline image
GLP-1 Demand Is Soaring. 2 Stocks That Could Benefit From This (Hint: Not Eli Lilly or Novo Nordisk) ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Eli Lilly Just Scored Europe's First Weight Loss Pill Approval -- and the Growth Story Keeps Getting Bigger ↗
Via The Motley Fool

Frequently Asked Questions

Is Novo Nordisk A/S Common Stock publicly traded?
Yes, Novo Nordisk A/S Common Stock is publicly traded.
What exchange does Novo Nordisk A/S Common Stock trade on?
Novo Nordisk A/S Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Novo Nordisk A/S Common Stock?
The ticker symbol for Novo Nordisk A/S Common Stock is NVO on the New York Stock Exchange
What is the current price of Novo Nordisk A/S Common Stock?
The current price of Novo Nordisk A/S Common Stock is 43.19
When was Novo Nordisk A/S Common Stock last traded?
The last trade of Novo Nordisk A/S Common Stock was at 09/17/26 07:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.